Seventy patients benefited from molecular analysis with the local high throughput sequencing AML minimal panel searching for mutations of NPM1, FLT3ITD, IDH1, IDH2, ASXL1, RUNX1, TP53 at diagnosis. Here, TP53 is linked to acute myeloid leukemia.